01 14Repatha
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 43
2019 Revenue in Millions : 27
Growth (%) : 57
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 887
2019 Revenue in Millions : 661
Growth (%) : 34
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 48
2020 Revenue in Millions : 43
Growth (%) : 21
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 1,117
2020 Revenue in Millions : 887
Growth (%) : 26
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 1,296
2021 Revenue in Millions : 1,117
Growth (%) : 16
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 47
2021 Revenue in Millions : 49
Growth (%) : -4
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 1,635
2022 Revenue in Millions : 1,296
Growth (%) : 26
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2017 Revenue in Millions : 319
2016 Revenue in Millions : 141
Growth (%) : 126
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2018 Revenue in Millions : 550
2017 Revenue in Millions : 319
Growth (%) : 72%
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2016 Revenue in Millions : 141
2015 Revenue in Millions : 10
Growth (%) : 1,310
LOOKING FOR A SUPPLIER?